Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-315.71%
operating margin TTM
-318.7%
revenue TTM
2.15 Million
revenue per share TTM
0.13$
valuation ratios | |
|---|---|
| pe ratio | -4.82 |
| peg ratio | -0.05 |
| price to book ratio | 0.94 |
| price to sales ratio | 10.74 |
| enterprise value multiple | -7.53 |
| price fair value | 0.94 |
profitability ratios | |
|---|---|
| gross profit margin | 99.26% |
| operating profit margin | -318.7% |
| pretax profit margin | -315.55% |
| net profit margin | -315.71% |
| return on assets | -22.13% |
| return on equity | -29.67% |
| return on capital employed | -24.15% |
liquidity ratios | |
|---|---|
| current ratio | 13.04 |
| quick ratio | 13.04 |
| cash ratio | 12.23 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 267.15 |
| days of payables outstanding | 1,950.70 |
| cash conversion cycle | -1,683.54 |
| receivables turnover | 1.37 |
| payables turnover | 0.19 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -18.80 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.12 |
| cash per share | 15.66 |
| operating cash flow per share | -2.95 |
| free cash flow operating cash flow ratio | 1.06 |
| cash flow coverage ratios | -18.80 |
| short term coverage ratios | -18.80 |
| capital expenditure coverage ratio | -16.93 |
Frequently Asked Questions
When was the last time Atrium Therapeutics, Inc. (NASDAQ:RNA) reported earnings?
Atrium Therapeutics, Inc. (RNA) published its most recent earnings results on 31-03-2026.
What is Atrium Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Atrium Therapeutics, Inc. (NASDAQ:RNA)'s trailing twelve months ROE is -29.67%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Atrium Therapeutics, Inc. (RNA) currently has a ROA of -22.13%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RNA's net profit margin stand at?
RNA reported a profit margin of -315.71% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RNA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 13.04 in the most recent quarter. The quick ratio stood at 13.04, with a Debt/Eq ratio of 0.01.